Scholarlink

Purpose <p>To report clinical characteristics and outcome of patients with Fanconi anemia (FA) in a resource-limited setting.</p> Methods <p>We retrospectively analyzed data from 46 patients with FA diagnosed between January 2005 and December 2021.</p> Results <p>Forty-six children were included. Parental consanguinity was found among 84% of patients. A family history of FA and malignancy was reported in 43% and 13%, respectively. Most patients presented with hematological manifestations: anemia in 74% patients followed by thrombocytopenia in 72%. Ten out of the eighteen patients who received androgen therapy showed an initial good response to treatment. Nine (19.6%) of the patients had myelodysplasia; one of them, with 47, XY, + 1, went on to develop acute myeloid leukemia (AML). The median (IQR) age at development of MDS was 8.13 (2.15–10.65) years. Overall, 5/46 patients developed AML with a median (IQR) age at AML diagnosis of 11.9 (10.53–14.17) years. All five patients with AML died: four with progressive disease, and one patient died during HSCT. The median time of follow-up in our study was 9&#xa0;years. Overall, we report seven mortalities with a median age at death of 13&#xa0;years and a median time from diagnosis to death of 2.4&#xa0;years. The main cause of death in our cohort was AML in five patients, while two patients died with infection and bleeding.</p> Conclusion <p>AML remains a leading cause of mortality in patients with FA. Close monitoring for early detection of myelodysplasia and access to HSCT a key to improved survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical features and outcome of children with Fanconi anemia in a resource-limited setting: a single-center study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月13日

查看全文
  • Sara Makkeyah,
  • Nihal Hussien,
  • Sherein Shalaby,
  • Mennat Allah Magdy,
  • Mohammad El- Naghi,
  • Ahmed Afifi

摘要

Purpose

To report clinical characteristics and outcome of patients with Fanconi anemia (FA) in a resource-limited setting.

Methods

We retrospectively analyzed data from 46 patients with FA diagnosed between January 2005 and December 2021.

Results

Forty-six children were included. Parental consanguinity was found among 84% of patients. A family history of FA and malignancy was reported in 43% and 13%, respectively. Most patients presented with hematological manifestations: anemia in 74% patients followed by thrombocytopenia in 72%. Ten out of the eighteen patients who received androgen therapy showed an initial good response to treatment. Nine (19.6%) of the patients had myelodysplasia; one of them, with 47, XY, + 1, went on to develop acute myeloid leukemia (AML). The median (IQR) age at development of MDS was 8.13 (2.15–10.65) years. Overall, 5/46 patients developed AML with a median (IQR) age at AML diagnosis of 11.9 (10.53–14.17) years. All five patients with AML died: four with progressive disease, and one patient died during HSCT. The median time of follow-up in our study was 9 years. Overall, we report seven mortalities with a median age at death of 13 years and a median time from diagnosis to death of 2.4 years. The main cause of death in our cohort was AML in five patients, while two patients died with infection and bleeding.

Conclusion

AML remains a leading cause of mortality in patients with FA. Close monitoring for early detection of myelodysplasia and access to HSCT a key to improved survival.